Business
Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR
The new platform delivers unmatched quantitation, robustness, and throughput to support clinical translation of spatial proteomics assays ORLANDO,
About this update from Bruker Corporation
[{"type":"text","content":"\nThe new platform delivers unmatched quantitation, robustness, and throughput to support clinical translation of spatial proteomics assays\n\n\n ORLANDO, Fla.--(BUSINESS WIRE)--\nBruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the development of diagnostic and prognostic assays by delivering unprecedented quantitative performance, robustness, and flexibility. CellScape XR addresses a critical bottleneck in translational research by enabling high-throughput, reproducible spatial proteomics at a scale and rigor required for translational and clinical applications.\n\n\nAs spatial proteomics moves from discovery to translational research and to diagnostic development, researchers face increasing demands for assay reproducibility, standardization, quantitative confidence, and throughput across large clinical cohorts. CellScape XR incorporates advances in optics, fluidics, and protocols to specifically meet these needs, combining highly multiplexed protein detection with improved throughput and workflow flexibility, without compromising spatial resolution or data quality.\n\n\nAdditionally, Bruker has supported collaborations to advance translational spatial biology on the CellScape platform, including at the University Hospital Schleswig-Holstein, Kiel (UKSH). UKSH has completed analysis of more than 1000 clinically annotated samples with plans to extend the study to approximately 3,000 patient samples.\n\n\n“We are deploying the CellScape platform to develop translational predictive and prognostic spatial-omics panels and AI-informed signatures across multiple solid tumor indications,” said Niclas C. Blessin MD, Assistant Professor of Pathology at UKSH. “The quantitative consistency and throughput of the CellScape platform allows us to evaluate spatially resolved biomarkers across large patient cohorts, which is essential for building clinically meaningful prognostic assays. Our long-term goal is to translate this work to the clinic, and CellScape XR provides the technical foundation to get there.”\n\n\nWith the launch of CellScape XR, Bruker reinforces its commitment to supporting the full lifecycle of spatial proteomics—from discovery research to translational research to clinical assay development. By enabling scalable, quantitative spati...